<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311766</url>
  </required_header>
  <id_info>
    <org_study_id>SSEB</org_study_id>
    <secondary_id>0003031</secondary_id>
    <nct_id>NCT00311766</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RegeneRx Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RegeneRx Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate a treatment to enhance the healing of acute and
      chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with
      Epidermolysis Bullosa (EB), by the known activity of thymosin beta 4 (Tβ4). Funding Source -
      FDA Office of Orphan Product Development (OOPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EB is a group of genetic diseases characterized by skin-blistering and lesion-formation after
      minor trauma to the skin. This family of disorders, most of which are inherited, range in
      severity from mild to the severely disabling and life-threatening. Tβ4 is a
      synthetically-produced copy of a naturally-occurring 43 amino acid peptide that has wound
      healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient availability and expiration of study drug
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>70 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Whose Wounds Have Healed</measure>
    <time_frame>56 days</time_frame>
    <description>Wound healing means that the wound has closed without any drainage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin Beta 4</intervention_name>
    <description>Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent form signed by the patient or patient's legal representative; also,
             if the patient is under the age of majority but capable of providing assent, signed
             assent from the patient

          -  Diagnosis of junctional or dystrophic EB.

          -  Patients who present with Hallopeau-Siemens subtype may be enrolled.

          -  At least one active, unroofed EB erosion on the limb or on the trunk.

          -  Lesion size 5 to 50 cm2, inclusive.

          -  Stable lesion present for 14-60 days before enrollment.

          -  More that one member in a family can be enrolled as long as that member is treated to
             a different cohort with an assurance that the study medication will not be shared.

          -  No clinically significant abnormalities (Grade 2 or higher on the National Cancer
             Institute [NCI] toxicity scale) on Screening laboratory tests, except for the
             following specific laboratory threshold result: albumin must be 2 g/dL or higher;
             hemoglobin must be 8 g/dL or higher.

        Exclusion Criteria:

          -  Clinical evidence of local infection of the index (targeted) lesion.

          -  Use of any investigational drug within the 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within the 30 days before
             enrollment.Inhaled steroids are allowed.

          -  Use of systemic antibiotics within the 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated wounds.

          -  Diabetes mellitus.

          -  Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed
             at Screening for female patients of childbearing potential.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Crockford</last_name>
    <role>Study Director</role>
    <affiliation>RegeneRx Biopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <results_first_submitted>May 22, 2013</results_first_submitted>
  <results_first_submitted_qc>June 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2013</results_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermolysis Bullosa</keyword>
  <keyword>cutaneous wound-healing</keyword>
  <keyword>chronic wound-healing</keyword>
  <keyword>Thymosin Beta 4</keyword>
  <keyword>laminin-5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In:22 February 2006; Last Patient In: 6 July 2010 Locations: Medical Centers</recruitment_details>
      <pre_assignment_details>No wash out or run-in periods in this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Topical administration of placebo gel, 0% Thymosin Beta 4, qd up to 56 days
Placebo : Topical administration, 0.00% qd up to 56 days</description>
        </group>
        <group group_id="P2">
          <title>Thymosin Beta 4</title>
          <description>Topical administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Thymosin Beta 4 : Topical administration, 0.01%, 0.03%, and 0.1% gel, qd up to 56 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Topical administration of placebo gel, 0% Thymosin Beta 4, qd up to 56 days
Placebo : Topical administration, 0.00% qd up to 56 days</description>
        </group>
        <group group_id="B2">
          <title>Thymosin Beta 4</title>
          <description>Topical administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Thymosin Beta 4 : Topical administration, 0.01%, 0.03%, and 0.1% gel, qd up to 56 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Whose Wounds Have Healed</title>
        <description>Wound healing means that the wound has closed without any drainage</description>
        <time_frame>56 days</time_frame>
        <population>The population for efficacy analysis will be the Full Analysis (FA) population. The FA analysis included all patients who were randomized and received at least one dose of study medication and who had at least one baseline efficacy parameter recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Topical administration of placebo gel, 0% Thymosin Beta 4, qd up to 56 days
Placebo : Topical administration, 0.00% qd up to 56 days</description>
          </group>
          <group group_id="O2">
            <title>Thymosin Beta 4</title>
            <description>Topical administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Thymosin Beta 4 : Topical administration, 0.01%, 0.03%, and 0.1% gel, qd up to 56 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose Wounds Have Healed</title>
          <description>Wound healing means that the wound has closed without any drainage</description>
          <population>The population for efficacy analysis will be the Full Analysis (FA) population. The FA analysis included all patients who were randomized and received at least one dose of study medication and who had at least one baseline efficacy parameter recorded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary population was the Full Analysis(FA)population. The FA population included all patients who were randomized and received at least one dose of study medication and who had at least one baseline efficacy parameter recorded</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>ANCOVA</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>70 days</time_frame>
        <population>The population for safety analysis included all patients who were randomized and received at least one dose of study medication and had at one safety parameter recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Topical administration of placebo gel, 0% Thymosin Beta 4, qd up to 56 days
Placebo : Topical administration, 0.00% qd up to 56 days</description>
          </group>
          <group group_id="O2">
            <title>Thymosin Beta 4</title>
            <description>Topical administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Thymosin Beta 4 : Topical administration, 0.01%, 0.03%, and 0.1% gel, qd up to 56 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <population>The population for safety analysis included all patients who were randomized and received at least one dose of study medication and had at one safety parameter recorded.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected within 70 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Topical administration of placebo gel, 0% Thymosin Beta 4, qd up to 56 days
Placebo : Topical administration, 0.00% qd up to 56 days</description>
        </group>
        <group group_id="E2">
          <title>Thymosin Beta 4</title>
          <description>Topical administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Thymosin Beta 4 : Topical administration, 0.01%, 0.03%, and 0.1% gel, qd up to 56 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <description>Cellulitis was resolved in 27 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study leading to randomizing 30 of the 36 participants planned. This was due to the small pool of participants and therefore resulting in low availability of eligible participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director, David R. Crockford</name_or_title>
      <organization>RegeneRx Biopharmaceuticals, Inc.</organization>
      <phone>617-285-5588</phone>
      <email>dcrockford@regenerx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

